NASDAQ:DARE

Daré Bioscience (DARE) Stock Forecast, Price & News

$1.01

+0.03 (+3.06%)

(As of 05/30/2023 ET)

Compare

Today's Range: $0.96
▼
$1.02
50-Day Range: $0.97
▼
$1.06
52-Week Range: $0.82
▼
$1.47

Volume: 266,849 shs
Average Volume: 259,522 shs
Market Capitalization: $87.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 593.1% Upside
$7.00 Price Target
Short Interest: Healthy
0.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.33) to ($0.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

695th out of 1,009 stocks

Pharmaceutical Preparations Industry

352nd out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Daré Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Daré Bioscience has a forecasted upside of 593.1% from its current price of $1.01.
Amount of Analyst Coverage
Daré Bioscience has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.44% of the outstanding shares of Daré Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Daré Bioscience has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Daré Bioscience has recently decreased by 25.91%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Daré Bioscience does not currently pay a dividend.
Dividend Growth
Daré Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DARE.

2.0

News and Social Media Coverage

News Sentiment
Daré Bioscience has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Daré Bioscience this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Daré Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Daré Bioscience is held by insiders.
Percentage Held by Institutions
Only 9.19% of the stock of Daré Bioscience is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Daré Bioscience are expected to decrease in the coming year, from ($0.33) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Daré Bioscience is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Daré Bioscience is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Daré Bioscience has a P/B Ratio of 7.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

May 25, 2023 | msn.com

The Dare Brings Back Early-2000s NYC Rock for 12 Joyless Minutes on ‘The Sex EP’

May 17, 2023 | americanbankingnews.com

Financial Contrast: IVERIC bio (NASDAQ:ISEE) and Daré Bioscience (NASDAQ:DARE)

May 30, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 16, 2023 | finance.yahoo.com

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2023 Earnings Call Transcript

May 16, 2023 | yahoo.com

Everybody Wants a Piece of The Dare

May 16, 2023 | americanbankingnews.com

FY2027 Earnings Estimate for Daré Bioscience, Inc. (NASDAQ:DARE) Issued By HC Wainwright

May 13, 2023 | markets.businessinsider.com

Maxim Group Reaffirms Their Buy Rating on Daré Bioscience (DARE)

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Dare Bioscience (DARE) Buy Recommendation

May 30, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Daré Bioscience (DARE)

May 12, 2023 | marketwatch.com

Dare Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

May 11, 2023 | finanznachrichten.de

Daré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

May 11, 2023 | msn.com

Recap: Dare Bioscience Q1 Earnings

May 11, 2023 | finance.yahoo.com

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

May 10, 2023 | msn.com

Earnings Outlook For Dare Bioscience

May 9, 2023 | americanbankingnews.com

Daré Bioscience (DARE) to Release Earnings on Thursday

May 5, 2023 | msn.com

Dare County residents receive N.C Governor’s Volunteer Service Awards

May 4, 2023 | finance.yahoo.com

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

April 21, 2023 | americanbankingnews.com

Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Grows By 16.8%

April 20, 2023 | nytimes.com

Track Covid-19 in Dare County, North Carolina

April 20, 2023 | finance.yahoo.com

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

April 19, 2023 | finance.yahoo.com

David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany

April 18, 2023 | finance.yahoo.com

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

April 17, 2023 | finance.yahoo.com

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

April 17, 2023 | finance.yahoo.com

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

April 5, 2023 | finance.yahoo.com

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2022 Earnings Call Transcript

April 5, 2023 | americanbankingnews.com

Daré Bioscience, Inc. to Post FY2027 Earnings of $0.80 Per Share, HC Wainwright Forecasts (NASDAQ:DARE)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings: 3/30/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DARE
CUSIP: N/A
CIK: 1401914
Web: www.darebioscience.com
Phone: (858) 926-7655
Fax: 617-494-1544
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +612.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,950,000.00
Net Margins: N/A
Pretax Margin: -305.92%
Return on Equity: -162.16%
Return on Assets: -69.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.21
Quick Ratio: 1.21

Sales & Book Value

Annual Sales: $10 million
Price / Sales: 8.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.13 per share
Price / Book: 7.56

Miscellaneous

Outstanding Shares: 86,290,000
Free Float: 82,834,000
Market Cap: $84.81 million
Optionable: Not Optionable
Beta: 1.20

Key Executives

Sabrina Martucci Johnson
President, CEO, Secretary & Director

Mark Walters
Vice President-Operations

Lisa Walters-Hoffert
Chief Financial Officer

Christine Mauck
Medical Director

David Friend
Chief Scientific Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DARE shares.
View DARE analyst ratings or view top-rated stocks.
What is Daré Bioscience's stock price forecast for 2023?: 4 Wall Street research analysts have issued twelve-month price objectives for Daré Bioscience's stock. Their DARE share price forecasts range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 612.3% from the stock's current price.
View analysts price targets for DARE or view top-rated stocks among Wall Street analysts.
How have DARE shares performed in 2023?: Daré Bioscience's stock was trading at $0.83 at the beginning of the year. Since then, DARE stock has increased by 18.4% and is now trading at $0.9828.
View the best growth stocks for 2023 here.
Are investors shorting Daré Bioscience?: Daré Bioscience saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 378,600 shares, a drop of 25.9% from the April 30th total of 511,000 shares. Based on an average trading volume of 191,300 shares, the days-to-cover ratio is currently 2.0 days.
View Daré Bioscience's Short Interest.
When is Daré Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our DARE earnings forecast.
How were Daré Bioscience's earnings last quarter?: Daré Bioscience, Inc. (NASDAQ:DARE) posted its earnings results on Thursday, March, 30th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.04.

What other stocks do shareholders of Daré Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).
What is Daré Bioscience's stock symbol?: Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."
Who are Daré Bioscience's major shareholders?: Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.73%), Renaissance Technologies LLC (0.66%), State Street Corp (0.29%), Jane Street Group LLC (0.09%) and Virtu Financial LLC (0.04%).
View institutional ownership trends.
How do I buy shares of Daré Bioscience?: Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Daré Bioscience's stock price today?: One share of DARE stock can currently be purchased for approximately $0.98.
How much money does Daré Bioscience make?: Daré Bioscience (NASDAQ:DARE) has a market capitalization of $84.81 million and generates $10 million in revenue each year. The biotechnology company earns $-30,950,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How can I contact Daré Bioscience?: Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial